PETA DISTRIBUSI DAN RESISTENSI Acinetobacter baumannii DARI SPESIMEN KLINIK DI RSUD DR. ZAINOEL ABIDIN TAHUN 2018

Wilda Mahdani, Zinatul Hayati, Teuku Yusriadi

Abstract


Kemampuan hidup Acinetobacter baumannii pada berbagai keadaan dikombinasikan dengan resistensi berkaitan erat dengan Healthcare Associated Infections (HAIs). Kemunculan strain resisten telah banyak dilaporkan. Penelitian ini bersifat observasional deskriptif. Pemeriksaan spesimen klinik dilakukan di Laboratorium Mikrobiologi Klinik RSUD dr. Zainoel Abidin Banda Aceh. Isolat Acinetobacter baumannii dikumpulkan,  dilakukan uji kepekaan serta dinilai tingkat resistensinya. Angka insidensi Acinetobacter baumannii adalah 4,6% yang dominan terisolasi dari spesimen sputum. Strain resisten sangat umum dijumpai pada ruang rawat intensif, ruangan non intensif memiliki lebih banyak strain susceptible. Strain MDR menunjukkan kepekaan terhadap amikacin, trimethoprim-sulfamethoxazole, tobramycin, ampicillin-sulbactam, dan meropenem. Acinetobacter baumannii strain XDR hanya menunjukkan kepekaan yang masih baik terhadap amikacin. Data epidemiologi resistensi antibiotik adalah komponen utama Program Pengendalian Resistensi Antibiotik di rumah sakit.


Keywords


acinetobacter baumannii, healthcare associated infections, resistensi antimikroba

Full Text:

PDF

References


World Health Organization. Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. Geneva: World Health Organization; 2017.

Manchanda V, Sanchaita S, Singh NP. Multidrug resistant Acinetobacter. Journal of Global Infectious Diseases. 2012; 2(3): 291-304.

Gonzalez-Villoria AM, Valverde-Garduno V. Antibiotic-Resistant Acinetobacter baumannii Increasing Success Remains a Challenge as a Nosocomial Pathogen . Journal of Pathogens. 2016;2016:1–10.

Barrie A, Gorman M. Acinetobacter baumannii-The New MRSA? Eplasty [Internet]. 2016;16:ic10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27011781%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4796877

Kuo HY, Chao HH, Liao PC, Hsu L, Chang KC, Tung CH, et al. Functional characterization of Acinetobacter baumannii Lacking the RNA chaperone Hfq. Frontiers in Microbiology. 2017;8(Oct):1–12.

Montefour K, Frieden J, Hurst S, Helmich C, Headley D, Martin M, et al. Acinetobacter baumannii: An emerging multidrug-resistant pathogen in critical care. Critical Care Nurse. 2008;28(1):15–25.

Landman D, Quale JM, Mayorga D, Adedeji A, Vangala K, Ravishankar J, Flores C, Brooks S. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY. Archives of Internal Medicine . 2002;162: 1515–20.

Ayan M, Durmaz R, Aktas E, Durmaz B. Bacteriological, clinical and epidemiological characteristics of hospital-acquired Acinetobacter baumannii infection in a teaching hospital. Journal of Hospital Infection. 2003;54: 39–45.

Dijkshoorn L, Aucken H, Gerner-Smidt P, Janssen P, Kaufmann ME, Garaizar J, Ursing J, Pitt TL. Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. Journal of Clinical Microbiology. 1996; 34:1519-1525.

Aygun G, Demirkiran O, Utku T, Mete B, Urkmez S, Yilmaz M, Yasar H, Dikmen Y, Oztürk R. Environmental contamination during a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. Journal of Hospital Infection. 2002;52: 259–62.

Willemsen I, Bogaers-Hofman D, Winters M, Kluytmans J. Correlation between antibiotic use and resistance in a hospital: temporary and ward-specific observations. Infection. 2009, 37(5): 432-7.

Peraturan Menteri Kesehatan No.8 Tahun 2015 Tentang Program Pengendalian Resistensi Antibiotik di Rumah Sakit.

Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clinical Microbiology Reviews. 1996;9:148–65.

Seifert H, Dijkshoorn L, Gerner-Smidt P, Pelzer N, Tjernberg I, Vaneechoutte M. Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods. Journal of Clinical Microbiology. 1997;35: 2819–25.

Berlau J, Aucken H, Malnick H, Pitt T. Distribution of Acinetobacter species on skin of healthy humans. European Journal of Clinical Microbiology and Infectious Diseases. 1999;18:179–183.

Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerging Infectious Diseases. 2005;11(1):22–9.

Daoud Z, Mansour N, Masri K. Synergistic Combination of Carbapenems and Colistin. Open Journal of Medical Microbiology. 2013;2013(December):253–8.

Mahdani W. Dua sisi antibiotik. Diunduh tanggal 16 januari 2015. http://aceh.tribunnews.com/2015/11/21/dua-sisi-antibiotik.

Broek PJV. 2015. Course Prudent Use of Antibiotiks. Surabaya.

Madigan MT, Martinko JM, Parker J. Brock biology of microorganisms. 14th edition. Book News, Inc., Portland. USA; 2015.

European Centre for Disease Prevention and Control (eCDC). Acinetobacter spp.; antimicrobial categories and agents used to define MDR, XDR and PDR, Antimicrobial Resistance and Healthcare-associated Infections Programme, viewed 28 September 2014, http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Documents/table-5_Clinical_Microbiology_and_Infection.pdf.

Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement, CLSI, Pennsylvania, US; 2017.

Yuan WL, Shen YJ, Deng DY. Sex bias of Acinetobacter baumannii nosocomial infection. American Journal of Infection Control. 2018;46: 957-60.

Xiao D, Wang L, Zhang D, Xiang D, Liu Q, Xing X. Prognosis of patients with Acinetobacter baumannii infection in the intensive care unit: A retrospective analysis. Experimental and Therapeutic Medicine. 2017; 13(4): 1630–1633.

Uwingabiye J, Lemnouer A, Baidoo S, Frikh M, Kasouati J, Maleb A, Benlahlou Y, Bssaibis F, Mbayo A, Doghmi N, Abouelalaa K, Baite A, Ibrahimi A, Elouennass M. Intensive care unit-acquired Acinetobacter baumannii infections in a Moroccan teaching hospital: epidemiology, risk factors and outcome. Germs. 2017 ; 7(4): 193–205.

Jung JY, Park MS, Kim SE, Park BH, Son JY, Kim EY, Lim JE, Lee SK, Lee SH, Lee KJ, Kang YA, Kim SK, Chang J, Kim YS. Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC Infectious Diseases. 2010; (2010): 10:228.

Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: Emergence of a successful pathogen. Clinical Microbiology Reviews. 2008;21(3):538–82.

Rodríguez-Baño J, Martí S, Soto S, Fernandez-Cuenca F, Cisneros JM, Pachon J, Pascual A, Martínez-Martínez L, McQueary C, Actis LA, Vila J, Spanish Group for the Study of Nosocomial Infections (GEIH). Biofilm formation in Acinetobacter baumannii: associated features and clinical implications. Clinical Microbiology and Infection. 2008; 14: 276–278.

Kaplan JB. Antibiotic-induced biofilm formation. The International Journal of Artificial Organs. 201; 34: 737–751.




DOI: https://doi.org/10.29103/averrous.v6i1.2666

Article Metrics

 Abstract Views : 609 times
 PDF Downloaded : 13 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Wilda Mahdani, Zinatul Hayati, Teuku Yusriadi

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.


Print ISSN :
2477-5231
Online  ISSN
:
2502-8715

Publisher:
Unimal Logo

Fakultas Kedokteran Universitas Malikussaleh
Kampus Fakultas Kedokteran Universitas Malikussaleh, Jl. Meunasah, Uteunkot Cunda, Lhokseumawe, 24351, Provinsi Aceh, Tel/fax : 081376575984, Email: averrous@unimal.ac.id

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.